A new systematic review published in the World Journal of Pediatrics proposes a genetic framework for understanding and classifying a group of inflammatory conditions that resemble Behçet’s disease but often defy traditional diagnosis. The concept, known as Behçet’s spectrum disorders (BSD), aims to help clinicians recognize these conditions earlier and prioritize genetic testing in children with atypical symptoms.
Behçet’s disease is a systemic vasculitis characterized by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical, complicating diagnosis. Furthermore, a growing number of monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms, yet they are biologically distinct and require different therapeutic approaches. This diagnostic overlap frequently leads to misdiagnosis, inappropriate treatment, and prolonged suffering.
The research team from Peking Union Medical College Hospital in Beijing has published a review article in the World Journal of Pediatrics (DOI: 10.1007/s12519-026-01035-4) that comprehensively maps out the Behçet’s spectrum disorders. The researchers propose a tiered classification: “core Behçet’s spectrum disorders (BSD)” for monogenic diseases that directly converge on Behçet’s-defining inflammatory pathways, and “peripheral BSD” for conditions with partial clinical overlap or indirect mechanistic connections.
The core BSD tier comprises monogenic diseases that directly disrupt NF‑κB or JAK‑STAT signaling—specifically HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration and show strong convergence on BD‑relevant inflammatory circuits. The peripheral BSD tier includes polygenic or multifactorial entities such as recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8‑associated disease.
“We’re not saying these are all the same disease—they’re not,” the authors said. “But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn’t quite fit Behçet’s criteria, the BSD framework gives us a roadmap for what to test for and why.” They emphasized that the framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to very different treatments.
Clinically, the BSD framework enables earlier recognition of Behçet‑like phenotypes and guides rational genetic testing, allowing targeted therapies—such as IL‑1, TNF, or JAK inhibitors—for specific subsets. It also helps exclude non‑spectrum mimics, avoiding unnecessary investigations and expediting effective care. Scientifically, it unifies disparate inflammatory disorders under shared pathogenic axes, fostering collaborative research and paving the way for biomarker discovery and mechanism‑based trials.
Ultimately, this framework empowers pediatricians to move beyond trial‑and‑error management towards precision medicine, offering tangible hope for children with complex, refractory inflammatory conditions that have long defied conventional diagnosis and treatment. The review was supported by the National Key R&D Program of China and other funding sources, as noted in the original article.
